Exec Chat: Catching Up With Drug-Device Developers Sequana At LSX
Executive Summary
The company’s dual drug-device development pipeline is progressing well, with the company expecting its device, the Alfapump, to hit US clinics in 2025.
You may also be interested in...
Exec Chat: Sequana Medical Pursues Dual Device-Drug Strategy For Fluid Overload
Speaking to Medtech Insight, Sequana Medical’s CEO discussed the company’s two technologies for combating fluid overload whilst explaining that, sometimes, chasing approval as a drug can be the best way to ensure easy market access.
Investor Eye: A Licensing-Based Approach May Be Best For Revolutionary IP
Keeping a firm grip on one’s IP is a cornerstone of most innovative businesses. However, Robert Cote, CEO of Cote Capital, believes that if the idea is good enough to keep close, it’s good enough to license out.
The Illumina Shareholder Votes Are In, And Nobody Got What They Wanted
Carl Icahn was successful in ousting Illumina’s chair, however its CEO, Francis deSouza remains. Both analysts and investors believe this could further encourage Illumina to divest Grail.